Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
30–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\- Completion of the parent study, Study M15-736 or Study M20-339.
You may not be if
\- Participant considered by the investigator to be an unsuitable candidate to receive ABBV-951 for any reason.
Clareo Health | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
